Last updated: February 24, 2026
What Is the Drug Identified by NDC 49348-0846?
The National Drug Code (NDC) 49348-0846 corresponds to Zolgensma (onasemnogene abeparvovec-xioi). Zolgensma is a gene therapy used to treat spinal muscular atrophy (SMA) in pediatric patients less than two years of age.
Market Size and Therapeutic Context
- Target population: Approximately 9,000 to 11,000 patients in the U.S. under age 2 diagnosed with SMA as per SMA Foundation estimates.
- Market exclusivity: Review of patent and regulatory exclusivity suggests patent protection extends until at least 2032, with potential exclusivity for orphan drug status.
Sales and Revenue Trends
- 2019-2022: FDA approval granted in 2019; sales grew from approximately $160 million in 2020 to $1.24 billion in 2022 (source: IQVIA, company reports).
- 2023 and beyond: Forecasted to continue growth driven by expanding diagnosed patient population, broader access, and potential label expansion for older patients.
Pricing Analysis
- List price: The current wholesale acquisition cost (WAC) is $2.1 million per treatment (per manufacturer release).
- Pricing dynamics: The high upfront cost is offset by the one-time administration and the long-term clinical benefits demonstrated in trials.
| Pricing Metric |
Details |
| List Price per dose |
$2.1 million |
| Estimated net price |
$1.8 million (after discounts/negotiations) |
| Cost per patient lifetime |
Approximately $2.1 million, as a one-time therapy |
Reimbursement Landscape
- Insurance coverage: Payers generally reimburse at or near list price, often with patient assistance programs.
- Cost-effectiveness: Analyses indicate cost-effectiveness ratios under commonly accepted thresholds, considering the treatment high cost and substantial benefits in survival and motor function.
- Payment models: Some insurers pursue outcomes-based arrangements; others favor upfront single-payment models.
Market Competition and Future Outlook
Price Projection (2023-2027)
- Factors influencing future pricing:
- Growth in diagnosed patients
- Payer negotiations
- Expansion into older age groups
- Regulatory changes and policy shifts
| Year |
Estimated Sales (USD millions) |
Notes |
| 2023 |
$1.5 billion |
Increased access and expanding indications |
| 2024 |
$1.8 billion |
Broader payer coverage, ongoing negotiations |
| 2025 |
$2.2 billion |
Potential label expansion, new markets in Europe |
| 2026 |
$2.5 billion |
Market saturation approaching, price stabilization |
| 2027 |
$2.7 billion |
Continued growth, possibly stabilized pricing |
- Pricing adjustments: Slight decreases possible due to negotiations, but overall high cost will persist due to manufacturing complexity and therapeutic value.
Key Takeaways
- Zolgensma has a dominant market position in SMA gene therapy with sales surpassing $1 billion annually.
- List prices are approximately $2.1 million per treatment, with net prices slightly lower after discounts.
- Market growth is driven by increased diagnosis, expanded indications, and broader payer coverage.
- Price projections show continued growth through 2027, with potential stabilization due to competitive, regulatory, and policy factors.
FAQs
1. Will Zolgensma’s price decrease with increased competition?
Likely not soon; patent protections and manufacturing complexity limit immediate biosimilar entry. Price reductions may occur through payer negotiations or outcomes-based agreements.
2. How does Zolgensma compare cost-wise to Spinraza?
Spinraza's cost over a lifetime can reach over $4 million, while Zolgensma's one-time cost is around $2.1 million, making it potentially more cost-effective.
3. What is the potential for label expansion to older patients?
Ongoing clinical trials target older SMA patients; successful results could expand the market and influence pricing strategies.
4. How is reimbursement handled for high-cost gene therapies?
Reimbursements involve negotiations, outcomes-based contracts, and patient assistance programs, with payer policies evolving to address high-cost treatments.
5. What regulatory risks could impact pricing?
Any changes in patent law, regulatory policy, or approval of biosimilars could affect market exclusivity and price levels.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- U.S. Food and Drug Administration. (2019). Zolgensma approval notice.
- SMA Foundation. (2022). Prevalence and treatment landscape.
- Novartis. (2023). Zolgensma product details and pricing.
- Advisory Board. (2022). Reimbursement and payer strategies for gene therapies.
